Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
Okumura S, Ishihara M, Kiyota N, Yakushijin K, Takada K, Kobayashi S, Ikeda H, Endo M, Kato K, Kitano S, Matsumine A, Nagata Y, Kageyama S, Shiraishi T, Yamada T, Horibe K, Takesako K, Miwa H, Watanabe T, Miyahara Y, Shiku H.
Okumura S, et al. Among authors: miwa h.
BMJ Open. 2022 Nov 14;12(11):e065109. doi: 10.1136/bmjopen-2022-065109.
BMJ Open. 2022.
PMID: 36375974
Free PMC article.